Shabafrouz Keyvan, Bauer Jean, Berthold Dominik R
Centre pluridisciplinaire d'oncologie CHUV, 1011 Lausanne.
Rev Med Suisse. 2010 May 26;6(250):1057-8, 1060-1.
Despite major progress in the understanding of biological mechanisms underlying metastatic prostate cancer, the treatment of men with advanced prostate cancer remains challenging. Several randomized controlled trials with promising or positive results are underway or just released. Here we discuss new treatments which might be used in clinic in the near future: hormonal treatments (Abiraterone and MDV3100), a new chemotherapy (Cabazitaxel), a cellular vaccine (Sipuleucel-T), anti-angiogenic drugs (Bevacizumab, Aflibercept), a new radioactive treatment (Alpharadin) and a new bone-protective agent (Deno-sumab).
尽管在理解转移性前列腺癌的生物学机制方面取得了重大进展，但晚期前列腺癌男性患者的治疗仍然具有挑战性。几项结果有前景或呈阳性的随机对照试验正在进行或刚刚公布。在此，我们讨论一些可能在不久的将来应用于临床的新疗法：激素疗法（阿比特龙和MDV3100）、一种新的化疗药物（卡巴他赛）、一种细胞疫苗（西妥昔单抗）、抗血管生成药物（贝伐单抗、阿柏西普）、一种新的放射性治疗（锶-89）和一种新的骨保护剂（地诺单抗）。
